NCT07492160 Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms
| NCT ID | NCT07492160 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Jefferson Drapkin |
| Condition | Pregnancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 348 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 348 participants in total. It began in 2026-03-16 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are: Does cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss? Does cabergoline reduce the severity of breast symptoms and associated bother compared with placebo? Researchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss. Participants will: Complete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure Receive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure Complete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother A subset of participants will provide blood samples at selected time points to measure serum prolactin levels
Eligibility Criteria
Inclusion Criteria: * Pregnant people aged 18 years or older * Gestational age between 12 and 18 weeks * Undergoing treatment for spontaneous or induced abortion at Maimonides Medical Center * Able to provide informed consent * Willing and able to complete study surveys Exclusion Criteria: * Prior mastectomy * Currently breastfeeding * Current use of a dopamine agonist or dopamine antagonist medication * Known contraindication to Cabergoline according to the medication prescribing information
Contact & Investigator
June Ng, MD
PRINCIPAL INVESTIGATOR
Maimonides Medical Canter
Frequently Asked Questions
Who can join the NCT07492160 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07492160 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07492160 currently recruiting?
Yes, NCT07492160 is actively recruiting participants. Contact the research team at JuNg@maimo.org for enrollment information.
Where is the NCT07492160 trial being conducted?
This trial is being conducted at Brooklyn, United States.
Who is sponsoring the NCT07492160 clinical trial?
NCT07492160 is sponsored by Jefferson Drapkin. The principal investigator is June Ng, MD at Maimonides Medical Canter. The trial plans to enroll 348 participants.